Safety assessment of So‑cheong‑ryong‑tang: Subchronic toxicity study in Crl:CD Sprague Dawley rats

Lee,Mee‑Young; Seo,Chang‑Seob; Cha,Shin‑Woo; Shin,Hyeun‑Kyoo

doi:10.3892/mmr.2014.2114

Safety assessment of So‑cheong‑ryong‑tang: Subchronic toxicity study in Crl:CD Sprague Dawley rats

Authors:
- Mee‑Young Lee
- Chang‑Seob Seo
- Shin‑Woo Cha
- Hyeun‑Kyoo Shin
View Affiliations

Affiliations: Basic Herbal Research Group, Korea Institute of Oriental Medicine, Yuseong‑gu, Daejeon 305‑811, Republic of Korea, Division of Non‑clinical Studies, Korea Institute of Toxicology, Yuseong‑gu, Daejeon 305‑343, Republic of Korea
Published online on: April 3, 2014 https://doi.org/10.3892/mmr.2014.2114
Pages: 2273-2282

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

So‑cheong‑ryong‑tang, an oriental herbal formula, is used in Korea for treating pulmonary disorders, including asthma, bronchitis and allergic diseases. The objective of the present study was to investigate the potential adverse effects, if any, of subchronic administration of So‑cheong‑ryong‑tang aqueous extract (SCRT) in male and female rats. In the present study, 0, 1,000, 2,000 and 5,000 mg/kg/day of SCRT was administered to Crl:CD Sprague Dawley rats (10/gender/group) for 13 weeks via oral gavage. Administration of the SCRT did not result in any mortality. There were no clinical or ophthalmological signs, changes in urinalysis, body weight, food consumption, gross findings, hematology, serum biochemistry, organ weight or histopathology attributable to the administration of SCRT. Any alterations noted were incidental and consistent with those historically observed in the age and strain of rats used in the present study. Based on the results of the present study, the no observed adverse effect level for SCRT under the present experimental conditions was determined to be 5,000 mg/kg/day, the highest dose assessed, for both genders.

View Figures

View References

1	Wills RB, Bone K and Morgan M: Herbal products: active constituents, modes of action and quality control. Nutr Res Rev. 13:47–77. 2000. View Article : Google Scholar : PubMed/NCBI
2	Seeff LB: Herbal hepatotoxicity. Clin Liver Dis. 11:577–596. 2007. View Article : Google Scholar : PubMed/NCBI
3	Tang JL, Liu BY and Ma KW: Traditional Chinese medicine. Lancet. 372:1938–1940. 2008. View Article : Google Scholar
4	Sucher NJ: Insights from molecular investigations of traditional Chinese herbal stroke medicines: implications for neuroprotective epilepsy therapy. Epilepsy Behav. 8:350–362. 2006. View Article : Google Scholar : PubMed/NCBI
5	Cosyns JP: Aristolochic acid and ‘Chinese herbs nephropathy’: a review of the evidence to date. Drug Saf. 26:33–48. 2003.
6	Veiga VF Jr, Pinto AC and Maciel MAM: Medicinal plants: safe cure? Quim Nova. 28:519–528. 2005. View Article : Google Scholar
7	Debelle FD, Vanherweghem JL and Nortier JL: Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74:158–169. 2008. View Article : Google Scholar : PubMed/NCBI
8	Ko E, Rho S, Lee EJ, Seo YH, Cho C, Lee Y, Min BI, Shin MK, Hong MC and Bae H: Traditional Korean medicine (SCRT) modulate Th/Th2 specific cytokine production in mice CD4⁺ T cell. J Ethnopharmacol. 92:121–128. 2004. View Article : Google Scholar : PubMed/NCBI
9	Lee MY, Shin IS, Seo CS, Kim JH, Han SR and Shin HK: Subchronic oral toxicity studies of the traditional herbal formula Bangpungtongseong-san in Crl:CD (SD) rats. J Ethnopharmacol. 144:720–725. 2012. View Article : Google Scholar : PubMed/NCBI
10	Barnes PM, Powell-Griner E, McFann K and Nahin RL: Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 27:1–19. 2004.
11	Firenzuoli F and Gori L: Herbal medicine today: clinical and research issues. Evid Based Complement Altern Med. 4:37–40. 2007. View Article : Google Scholar : PubMed/NCBI
12	Park MY, Choi HY, Kim JD, Lee HS and Ku SK: 28 days repeated oral dose toxicity test of aqueous extracts of Mahwangyounpae-tang, a polyherbal formula. Food Chem Toxicol. 48:2477–2482. 2010. View Article : Google Scholar : PubMed/NCBI
13	Giknis MLA and Clifford CB: Spontaneous neoplasms and survival in Wistar Han rats. Compilation of control group data. Charles River Laboratories; pp. 1–21. 2003
14	Matsuo R, Yamauchi Y, Kobashi M, Funasashi M, Mitoh Y and Adachi A: Role of parabrachial nucleus in submandibular salivary secretion induced by bitter taste stimulation in rats. Auton Neurosci. 88:61–73. 2001. View Article : Google Scholar : PubMed/NCBI
15	Kim JC, Kang BH, Shin CC, Kim YB, Lee HS, Kim CY, Han J, Kim KS, Chung DW and Chung MK: Subchronic toxicity of plant sterol esters administered by gavage to Sprague Dawley rats. Food Chem Toxicol. 40:1569–1580. 2002. View Article : Google Scholar : PubMed/NCBI
16	Burn CC, Peters A, Day MJ and Mason GJ: Long-term effects of cage-cleaning frequency and bedding type on laboratory rat health, welfare, and handleability: a cross-laboratory study. Lab Animal. 40:353–370. 2006. View Article : Google Scholar : PubMed/NCBI
17	Derelanko MJ: The Toxicologist’s Pocket Handbook. 2nd edition. Informa Healthcare; United Kingdom: pp. 1–20. 2008
18	Boorman GA, Eustis SL, Elwell MR, Montgomery CA Jr and Mackenzie WF: Pathology of the Fischer Rat Reference and Atlas. Academic Press; San Diego, CA: 1990
19	Haschek WM and Rousseaux CG: Fundamentals of Toxicologic Pathology. 2nd edition. Academic Press; San Diego, CA: pp. 1–8. 1998
20	Kim JC, Shin DH, Kim SH, Kim JK, Park SC, Son WC, Lee HS, Suh JE, Kim CY, Ha CS and Chung MK: Subacute toxicity evaluation of a new camptothecin anticancer agent CDK-602 administered by intravenous injection to rats. Regul Toxicol Pharmacol. 140:356–369. 2004. View Article : Google Scholar : PubMed/NCBI